Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
14 studies found for:    bombesin
Show Display Options
Rank Status Study
1 Completed
Has Results
68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer
Condition: Prostate Carcinoma
Interventions: Drug: 68Ga-DOTA-Bombesin;   Procedure: Magnetic Resonance Imaging (MRI) scan;   Procedure: Positron Emission Tomography (PET) scan
2 Recruiting 68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer
Condition: Prostate Cancer
Interventions: Radiation: 68Ga-RM2 (RM2);   Device: PET/CT Scan
3 Completed Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia
Conditions: Bronchopulmonary Dysplasia;   Prematurity
Intervention:
4 Completed PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers
Condition: Diagnostic Imaging
Intervention: Drug: Bombesin (68Ga) labeled (BAY86-7548)
5 Terminated PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: [68Ga]RM2;   Procedure: PET/CT
6 Recruiting 68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer
Conditions: Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma;   Stage IV Prostate Adenocarcinoma
Interventions: Procedure: Computed Tomography;   Drug: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548;   Other: Laboratory Biomarker Analysis;   Procedure: Positron Emission Tomography
7 Recruiting 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Condition: Prostate Adenocarcinoma
Interventions: Drug: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548;   Procedure: Magnetic Resonance Imaging;   Procedure: Positron Emission Tomography
8 Completed The Possible Effect Of Amniotic Fluid pH On Neonatal Morbidities In Maternal Inflammation/Infection Associated Pregnancies
Conditions: Respiratory Distress Syndrome;   Transient Tachypnea of Newborn;   Intrauterine Growth Retardation
Intervention: Device: Amniotic fluid analysis by blood gas device
9 Recruiting 68Ga-NOTA-Aca-BBN(7-14) PET/CT in Patients With Primary Gliomas
Condition: Glioma
Interventions: Drug: 68Ga-NOTA-Aca-BBN;   Device: PET/CT
10 Terminated Positron Emission Tomography/Computed Tomography (PET/CT) Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-4367 in Patients With Prostate Cancer and Healthy Volunteers
Condition: Diagnostic Imaging
Intervention: Drug: BAY86-4367
11 Terminated Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: computed tomography;   Procedure: magnetic resonance imaging;   Procedure: single photon emission computed tomography;   Radiation: technetium Tc 99m demobesin-4
12 Not yet recruiting Evaluate the Auxiliary Diagnostic Value of Circulating Tumor Cells in Benign and Malignant Lung Nodules
Condition: Solitary Pulmonary Nodule
Intervention:
13 Recruiting Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma
Condition: Lung Cancer, Small Cell
Intervention: Drug: GSK2879552
14 Recruiting Detection of Genetic Markers of Lung Cancer
Condition: Non-small Cell Lung Cancer
Interventions: Procedure: Biopsy of the major carinal area;   Procedure: Biopsy of abnormal & suspicious areas of the bronchial tree;   Procedure: Evaluation of the tumor for DNA mutations;   Procedure: Bronchoalveolar Lavage (BAL) for cytokine analysis;   Procedure: Correlation of flow cytometric & RT PCR for TNM stage;   Procedure: Analysis of lymph nodes

Study has passed its completion date and status has not been verified in more than two years.